Last updated: April 2, 2025
Sponsor: Xijing Hospital
Overall Status: Active - Recruiting
Phase
N/A
Condition
Kidney Disease
Kidney Failure
Renal Failure
Treatment
L-Arginine hydrochloride
Clinical Study ID
NCT06248359
KY20232170-C-1
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
adult patients (over 18 years)
underwent CPB assisted cardiac surgery
admitted to ICU
Exclusion
Exclusion Criteria:
congenital heart disease
underwent deep hypothermic circulatory arrest (DHCA)
with glomerular filtration rate (eGFR) below 30 mL/min/1.73 m²
Study Design
Total Participants: 7000
Treatment Group(s): 1
Primary Treatment: L-Arginine hydrochloride
Phase:
Study Start date:
December 01, 2023
Estimated Completion Date:
December 01, 2025
Connect with a study center
Xijing Hospital
Xi'an, Shaanxi 710032
ChinaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.